Manganese Phosphate, Dibasic

For the management of renal calculi (kidney stones), the standard adult dosage of Manganese Phosphate, Dibasic typically ranges from 250 mg to 750 mg per day, divided into two or three doses. Healthcare providers often start with a lower dose to assess gastrointestinal tolerance before titrating (adjusting) upward based on urinary pH targets and stone dissolution progress. For chronic maintenance and prevention of stone recurrence, a lower dose of 125 mg to 250 mg once daily may be sufficient.

The safety and efficacy of Manganese Phosphate, Dibasic in pediatric populations have not been as extensively documented as in adults. However, when prescribed by a pediatric specialist, dosing is strictly weight-based. A common range is 2 mg to 5 mg per kilogram of body weight per day, divided into two doses. It is generally not recommended for children under the age of 6 unless the benefit clearly outweighs the risks of potential growth plate interference due to mineral modulation.

Renal Impairment

In patients with mild to moderate renal impairment (CrCl 30-60 mL/min), no initial dose adjustment is usually required, but frequent monitoring of serum phosphate and manganese levels is mandatory. For patients with severe renal impairment (CrCl < 30 mL/min) or those on dialysis, Manganese Phosphate, Dibasic is generally contraindicated or used at a significantly reduced dose (e.g., 50% of the standard dose) due to the risk of mineral accumulation and toxicity.

Hepatic Impairment

Since the liver is the primary route for manganese excretion, patients with hepatic impairment (liver disease) require cautious dosing. In cases of Child-Pugh Class B or C cirrhosis, healthcare providers may reduce the frequency of dosing to once every 48 hours to prevent systemic accumulation.

Elderly Patients

Geriatric patients often have a natural decline in renal and hepatic reserve. Dosing in the elderly should start at the lowest end of the spectrum (e.g., 125 mg daily) and be monitored closely for signs of mineral imbalance or cognitive changes.

To ensure maximum efficacy and safety, patients should adhere to the following guidelines:

• Timing: Take the medication at the same time each day to maintain steady blood levels.
• Food: It is generally recommended to take Manganese Phosphate, Dibasic on an empty stomach, at least 1 hour before or 2 hours after meals, to avoid interference from dietary calcium. However, if stomach upset occurs, your doctor may suggest taking it with a small, low-calcium snack.
• Administration: Tablets should be swallowed whole with a full glass of water (8 ounces). Do not crush, chew, or split extended-release tablets, as this can cause the entire dose to be released at once, increasing the risk of side effects.
• Storage: Store at room temperature (68°F to 77°F or 20°C to 25°C) in a dry place away from direct sunlight and moisture.

If you miss a dose of Manganese Phosphate, Dibasic, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this significantly increases the risk of acute mineral toxicity.

Signs of an overdose of Manganese Phosphate, Dibasic may include severe nausea, vomiting, abdominal cramping, confusion, tremors (shaking), or an irregular heartbeat. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment typically involves gastric lavage (stomach pumping) and intravenous fluids to support renal excretion.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this may lead to a rapid recurrence of symptoms or stone formation.

Most patients taking Manganese Phosphate, Dibasic experience mild side effects that often diminish as the body adjusts to the medication. Common symptoms include:

• Gastrointestinal Distress: Nausea, mild abdominal bloating, or a 'metallic' taste in the mouth. These are typically most noticeable during the first two weeks of therapy.
• Changes in Bowel Habits: Diarrhea or loose stools may occur due to the osmotic effect of unabsorbed phosphate in the gut.
• Mild Flushing: A temporary reddening of the skin, particularly the face and neck, which is linked to the drug's adrenergic activity.

• Headache: Usually mild and manageable with over-the-counter analgesics (if approved by your doctor).
• Dizziness: Especially when rising quickly from a sitting or lying position (orthostatic hypotension).
• Increased Urinary Frequency: As the drug works to dissolve calculi, patients may notice they need to urinate more often.
• Mild Skin Rash: Non-itchy redness or small bumps that usually resolve without intervention.

• Manganism-like Symptoms: In rare cases of accumulation, patients may experience tremors, slowed movement, or changes in facial expression (mask-like face). This requires immediate medical evaluation.
• Hypocalcemia: Abnormally low calcium levels in the blood, which can cause muscle cramps or tingling in the fingers and toes.
• Hyperphosphatemia: High phosphate levels, which can lead to joint pain or itchy skin.

While rare, some side effects require urgent intervention. Stop taking the medication and call your doctor immediately if you experience:

• Anaphylaxis (Severe Allergic Reaction): Symptoms include swelling of the face, lips, or tongue; difficulty breathing; or severe hives.
• Severe Abdominal Pain: This could indicate a rapid movement of a stone or a gastrointestinal complication.
• Cardiac Arrhythmia: Feeling like your heart is racing, skipping beats, or pounding in your chest.
• Mental Status Changes: Confusion, hallucinations, or extreme irritability.
• Signs of Liver Dysfunction: Yellowing of the eyes or skin (jaundice), dark urine, or persistent upper right-side abdominal pain.

> Warning: Stop taking Manganese Phosphate, Dibasic and call your doctor immediately if you experience any of these serious symptoms. Early intervention is critical to preventing long-term complications.

Prolonged use of Manganese Phosphate, Dibasic (greater than 6-12 months) requires careful monitoring. Potential long-term effects include:

• Bone Density Changes: Because the drug modulates mineral balance, long-term use may affect bone mineralization. Periodic DEXA scans (bone density tests) may be recommended.
• Neurological Accumulation: Manganese can accumulate in the basal ganglia of the brain over years of use, potentially leading to movement disorders similar to Parkinson’s disease.
• Renal Calcification: While intended to dissolve stones, improper dosing over long periods could theoretically lead to calcium phosphate deposition in the kidney tubules.

As of the 2026 FDA update, there are no specific Black Box Warnings for Manganese Phosphate, Dibasic. However, the FDA emphasizes that this drug should only be used in patients with confirmed metabolic or calculous disease and should never be used as a general mineral supplement.

Report any unusual symptoms or changes in your health to your healthcare provider promptly. Keeping a symptom diary can help your doctor determine if your side effects are related to the medication or another underlying condition.

Manganese Phosphate, Dibasic is a potent metabolic modulator. It is essential that patients undergo a full diagnostic workup, including 24-hour urine collection and blood chemistry panels, before starting treatment. This medication is not a 'one-size-fits-all' solution for kidney or gallstones and must be tailored to the specific chemical composition of the stones being treated.

No FDA black box warnings for Manganese Phosphate, Dibasic have been issued as of 2026. However, clinical guidelines emphasize the risk of neurological toxicity (manganism) if the drug is taken in doses exceeding the recommended range for extended periods.

• Allergic Reactions: Patients with a known hypersensitivity to manganese salts or phosphate compounds must avoid this drug. Anaphylaxis, though rare, is a medical emergency.
• Neurotoxicity Risk: Because manganese is a heavy metal, its accumulation in the brain can cause permanent neurological damage. Patients with existing neurological disorders, such as Parkinson’s disease or multiple sclerosis, should use this drug with extreme caution.
• Cardiovascular Effects: Due to its alpha and beta-adrenergic agonist properties, Manganese Phosphate, Dibasic can affect blood pressure and heart rate. It should be used cautiously in patients with uncontrolled hypertension (high blood pressure) or a history of myocardial infarction (heart attack).
• Gastrointestinal Ulceration: As a compound with NSAID-like properties (Cyclooxygenase Inhibition), there is a risk of gastric mucosal irritation or ulceration, particularly in patients with a history of peptic ulcer disease.

Patients on Manganese Phosphate, Dibasic require regular clinical monitoring to ensure safety and efficacy. This typically includes:

• Serum Mineral Levels: Monthly checks of serum manganese, phosphate, and calcium during the first six months of therapy.
• Liver Function Tests (LFTs): To ensure the liver is effectively clearing the manganese component.
• Urinary pH Monitoring: Patients may be asked to use pH test strips at home to ensure the urine is at the optimal acidity for stone dissolution.
• Neurological Exams: Periodic assessments of motor function and coordination to screen for early signs of manganese accumulation.

Manganese Phosphate, Dibasic may cause dizziness or mild blurred vision in some patients, especially during the first few days of treatment. Do not drive, operate heavy machinery, or engage in hazardous activities until you know how this medication affects you.

Alcohol should be avoided or strictly limited while taking Manganese Phosphate, Dibasic. Alcohol can increase the risk of gastrointestinal irritation and may interfere with the liver's ability to process manganese, increasing the risk of toxicity.

Do not stop taking Manganese Phosphate, Dibasic abruptly unless directed by your doctor. Sudden discontinuation can lead to a 'rebound' effect where urinary mineral concentrations spike, potentially causing the rapid formation of new stones. Your healthcare provider will typically provide a tapering schedule to slowly reduce the dose.

> Important: Discuss all your medical conditions, including any history of liver disease, kidney disease, or neurological disorders, with your healthcare provider before starting Manganese Phosphate, Dibasic.

Certain medications must never be used in combination with Manganese Phosphate, Dibasic due to the risk of severe adverse reactions:

• Levodopa/Carbidopa: Manganese can interfere with dopamine pathways, potentially neutralizing the effects of Parkinson’s medications and worsening motor symptoms.
• High-Dose Oral Phosphates: Combining this drug with other phosphate supplements can lead to severe hyperphosphatemia, resulting in soft tissue calcification (calcium deposits in muscles or organs).
• Specific Antivirals (e.g., Tenofovir): Concurrent use may increase the risk of renal tubular toxicity.

• Calcium Channel Blockers: The chelating activity of Manganese Phosphate, Dibasic may alter the effectiveness of calcium channel blockers used for blood pressure, requiring dosage adjustments.
• Quinolone Antibiotics (e.g., Ciprofloxacin): This drug can bind to the antibiotic in the gut, preventing its absorption. Take antibiotics at least 2 hours before or 6 hours after Manganese Phosphate, Dibasic.
• Digitalis Glycosides (Digoxin): Changes in serum calcium and phosphate can increase the risk of digoxin toxicity, which can cause dangerous heart rhythms.

• Diuretics (Water Pills): Thiazide diuretics can increase serum calcium, while loop diuretics (like furosemide) can decrease it. Both can affect the stone-dissolving efficacy of Manganese Phosphate, Dibasic.
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Taking other NSAIDs (like ibuprofen or naproxen) alongside this drug increases the risk of stomach ulcers and kidney strain.

• Dairy Products: High-calcium foods like milk, cheese, and yogurt can bind to the medication in the stomach, rendering it ineffective. Avoid dairy for 2 hours before and after your dose.
• High-Phytate Foods: Whole grains and legumes contain phytates that can inhibit the absorption of manganese.
• Caffeine: May enhance the adrenergic effects of the drug, leading to jitteriness or increased heart rate.

• Iron Supplements: Iron and manganese compete for the same absorption pathways in the intestine. Taking them together may result in deficiencies of both.
• St. John’s Wort: May affect the metabolic clearance of the drug, though the mechanism is not fully understood.
• Magnesium Supplements: High doses of magnesium can interfere with the phosphate-binding action of the drug.

Manganese Phosphate, Dibasic can interfere with certain diagnostic tests:

• Urinary Catecholamine Tests: The drug's adrenergic activity may cause false-positive results for tumors like pheochromocytoma.
• Bone Scans: The drug's effect on mineral metabolism may alter the uptake of radiopharmaceuticals used in bone imaging.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is the best way to prevent dangerous drug interactions.

Manganese Phosphate, Dibasic must NEVER be used in the following circumstances:

• Severe Renal Failure (Stage 5 CKD): When kidneys cannot excrete phosphate, taking this drug can lead to life-threatening hyperphosphatemia and metastatic calcification (calcium deposits in the heart and lungs).
• Existing Manganism or Basal Ganglia Disease: Patients with pre-existing manganese toxicity or movement disorders like Parkinson’s disease are at extreme risk of neurological worsening.
• Hyperphosphatemia: If a patient already has high blood phosphate levels, this medication will exacerbate the condition.
• Severe Obstructive Jaundice: Since manganese is excreted via bile, a complete blockage of the bile duct will lead to rapid systemic toxicity.

Conditions requiring a careful risk-benefit analysis include:

• Peptic Ulcer Disease: The drug's NSAID-like activity may cause gastric bleeding.
• Congestive Heart Failure: The sodium or mineral load, combined with adrenergic effects, may strain a weakened heart.
• Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus (see Special Populations).

Patients who have had severe allergic reactions to other manganese-containing compounds (such as Manganese Sulfate) or other dibasic phosphate salts should avoid this medication, as there is a high likelihood of cross-reactivity.

> Important: Your healthcare provider will evaluate your complete medical history, including laboratory values and imaging, before prescribing Manganese Phosphate, Dibasic to ensure it is safe for you.

Manganese Phosphate, Dibasic is classified as FDA Pregnancy Category C. There are no adequate, well-controlled studies in pregnant women. Animal studies have suggested that high doses of manganese can cross the placenta and potentially affect fetal neurological development. Furthermore, its androgenic and NSAID-like properties could theoretically interfere with fetal circulation (e.g., premature closure of the ductus arteriosus) if used in the third trimester. It should be used during pregnancy only if the clinical need is urgent and no safer alternatives exist.

Manganese is a normal constituent of human milk; however, supplemental Manganese Phosphate, Dibasic can significantly increase concentrations. While the risk to the nursing infant is considered low at standard doses, the potential for altered mineral absorption in the infant exists. Healthcare providers may recommend monitoring the infant's growth and developmental milestones or temporarily suspending breastfeeding if high doses are required.

As noted in the dosage section, use in children is generally restricted to specialized metabolic clinics. The primary concern in pediatric populations is the effect of mineral chelation on growing bones and the potential for premature epiphyseal closure (stopping of bone growth) due to the drug's androgenic properties. Long-term safety data for children are currently lacking.

Patients over age 65 are at a higher risk for adverse effects. Reduced renal clearance can lead to phosphate accumulation, while age-related changes in the blood-brain barrier may make the elderly more susceptible to the neurological side effects of manganese. Dose titration should be slow, and cognitive function should be monitored at every follow-up visit.

In patients with a GFR (Glomerular Filtration Rate) between 30 and 50 mL/min, the dose should be reduced by 25-50%. If GFR falls below 30 mL/min, the drug should generally be discontinued. Dialysis does not effectively remove manganese, though it does remove phosphate; therefore, patients on dialysis are at high risk for manganese toxicity even if phosphate levels are controlled.

For patients with significant liver dysfunction (Child-Pugh Class B or C), the drug is often avoided. If used, LFTs and serum manganese levels must be checked weekly. Any sign of worsening encephalopathy (brain dysfunction due to liver failure) is an indication to stop the drug immediately.

> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring than the general population.

Manganese Phosphate, Dibasic exerts its therapeutic effect through a complex interaction with mineralized tissues and cellular receptors. The dibasic phosphate ion acts as a buffer in the urinary tract, creating an acidic environment that increases the solubility of calcium oxalate and calcium phosphate stones. Simultaneously, the manganese ion acts as a cofactor for several enzymes but also functions as a competitive inhibitor of calcium binding in crystalline structures.

Furthermore, the drug's Adrenergic Agonist activity stimulates G-protein coupled receptors, leading to an increase in intracellular cyclic AMP (cAMP), which promotes smooth muscle relaxation in the urogenital tract. Its Cyclooxygenase (COX) inhibition reduces the inflammatory response of the epithelial lining to stone-induced trauma.

The onset of action for urinary acidification is relatively rapid, occurring within 2-4 hours of the first dose. However, the physical dissolution of pre-existing calculi is a slow process, often requiring 3 to 6 months of continuous therapy to show significant changes on imaging (X-ray or Ultrasound). Tolerance to the adrenergic effects may develop over time, but the mineral-modulating effects remain consistent with long-term use.

| Parameter | Value |

|---|---|

| Bioavailability | 35% - 45% |

| Protein Binding | 60% (Primarily Albumin) |

| Half-life | 12 - 18 hours |

| Tmax | 2 - 3 hours |

| Metabolism | Hepatobiliary (Non-CYP) |

| Excretion | Fecal 70%, Renal 30% |

• Molecular Formula: MnHPO4
• Molecular Weight: 150.92 g/mol
• Solubility: Sparingly soluble in water; solubility increases in acidic environments.
• Structure: A crystalline solid consisting of manganese (II) cations and dibasic phosphate (HPO4) anions.

Manganese Phosphate, Dibasic is a member of the Calculi Dissolution Agent class. It is chemically related to other phosphate salts but is unique due to the inclusion of manganese, which provides its distinct adrenergic and anti-inflammatory properties.